Novo is looking for a new CEO. Bloomberg found the news in the Danish paper Berlingske, in which the exec told the paper it was unlikely he was going to stay at the company for the duration of his contract, which lapses in 2019.
Bloomberg notes that a replacement will have a strong leader to follow, writing that Rebien Soerensen “led the Danish company to one of the best stock market performances of any drugmaker over the past 14 years.”
